Curocell (KOSDAQ:A372320) secured regulatory approval from the South Korean Ministry of Food and Drug Safety to amend the Phase 1 clinical trials to evaluate the tolerability, safety, and efficacy of its CRC01 drug candidate, according to a Wednesday filing with the Korea Exchange.
The drug candidate is used in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia, while the Phase 2 trials will evaluate the efficacy and safety of CRC01 as assessed by independent evaluation.
The amendment will help separate the clinical trial protocols for independent and efficient operation of the acute lymphoblastic leukemia clinical trial.
Comments